Annexon, Inc. (ANNX)

Market Cap	276.91M
Revenue (ttm)	n/a
Net Income (ttm)	-188.78M
Shares Out	109.89M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,144,030
Open	2.675
Previous Close	2.650
Day's Range	2.510 - 2.690
52-Week Range	1.285 - 7.850
Beta	1.16
Analysts	Strong Buy
Price Target	13.00 (+413.83%)
Earnings Date	Nov 13, 2025

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company’s lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) th...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: ANNX
• Website: https://www.annexonbio.com

Analyst Summary

According to 5 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 413.83% from the latest price.

Price Target

$13.0

(413.83% upside)

Analyst Consensus: Strong Buy